BLOCK HIV/HCV

FACULTY PREAMBLE RESOURCE CENTER

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE & PARTNERSHIPS In collaboration with:

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

This activity is supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., and AbbVie Inc.

83

RESOURCE CENTER

PREAMBLE

FACULTY

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

CME/MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com 84

COLLABORATORS

FACULTY

We’d like to thank our local collaborators for their contributions and support.

FACULTY David L. Wyles, MD

Andrew I. Aronsohn, MD

Course Chair

Regional Cochair

Chief, Division of Infectious Diseases Denver Health Professor of Medicine University of Colorado School of Medicine Denver, Colorado

Co-Principal Investigator, HepCCATT Associate Professor of Medicine Faculty, MacLean Center for Clinical Medical Ethics Program Director Transplant Hepatology Fellowship University of Chicago Medicine Chicago, Illinois

Dr. David Wyles earned his medical degree from Northwestern University in Chicago, Illinois, and completed an internal medicine residency and infectious diseases fellowship at the University of Colorado. Dr. Wyles is a professor of medicine in the Division of Infectious Diseases at the University of Colorado and Chief of the Division of Infectious Diseases at Denver Health medical center.

Dr. Wyles’ research interests include hepatitis C virus (HCV) drug resistance and retreatment strategies and the treatment of HCV in vulnerable populations. An inaugural and current member of the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) HCV guidelines panel, he also serves on the International Antiviral Society (IAS) – USA Hepatitis Advisory Board and the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group (ACTG) Hepatitis Transformative Science Group. Clinically, Dr. Wyles is involved in the care of patients with HCV and HCV/human immunodeficiency virus (HIV) coinfection.

Dr. Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center. Dr. Aronsohn is also a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago. Dr. Aronsohn is the co-principal investigator of HepCCATT, a CDC-funded initiative to diagnose, link to care, and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting. Dr. Aronsohn is the colead of the treatment-experienced section of the AASLD/IDSA HCV guidance writing committee and was a member of National Academies of Medicine committee that wrote “A National Strategy for the Elimination of Hepatitis B and C.” He also has a busy clinical practice, which includes both general and transplant hepatology.

1

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

Nancy S. Reau, MD, FAASLD, AGAF

FACULTY

Regional Cochair Chief, Section of Hepatology Richard B. Capps Chair of Hepatology Associate Director, Solid Organ Transplantation Rush University Medical Center Chicago, Illinois Dr. Nancy Reau is Professor of Internal Medicine, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center in Chicago.

She received her medical degree from The Ohio State University College of Medicine in Columbus, where she completed a residency and fellowship in gastroenterology/ hepatology followed by a second fellowship in advanced transplant hepatology at Johns Hopkins Hospital in Baltimore, Maryland. Her primary research interests focus on viral hepatitis, from both a drug development and a clinical perspective, liver transplantation, and complications of chronic liver disease.

Dr. Reau has been an invited lecturer at numerous presentations focused on viral hepatitis, fatty liver disease, cirrhosis, and liver transplantation. A fellow of the American Gastroenterological Association and the American Association for the Study of Liver Diseases (AASLD), she is editor in chief of Clinical Liver Disease and was an author of the AASLD/IDSA hepatitis C guidance document. She was the committee chair of the AASLD public policy committee and a member of the AASLD practice guideline committee for 4 years.

Dr. Reau has authored or coauthored more than 100 peerreviewed articles published in journals such as Hepatology, Hepatitis Research and Treatment, and Clinics in Liver Disease. Cochair of the American Liver Foundation National Medical Advisory Committee, she sits on multiple advisory boards and is on the AASLD steering committee for the hepatitis C special interest group (SIG) as well as the American College of Gastroenterology training committee.

2

Oluwatoyin Adeyemi, MD Senior Director of HIV Services Cook County Health Director, CORE Hepatitis Clinic Associate Professor Department of Internal Medicine Division of Infectious Diseases Rush Medical College Chicago, Illinois Dr. Oluwatoyin (Toyin) Adeyemi is an infectious diseases physician with Cook County Health (CCH) and Associate Professor of Medicine at Rush Medical College. She received her medical degree from the University of Ibadan, Nigeria, and completed her internal medicine residency training at the University of Illinois at Chicago (UIC) and her infectious disease fellowship at the Joint Rush University/Cook County hospital training program.

Dr. Adeyemi has provided primary and specialty care to adults living with HIV and/or viral hepatitis at the Ruth M. Rothstein CORE Center since 1999 and is Director of the CORE Hepatitis Clinic. In 2018, she was appointed the Senior Director for HIV Services, CCH. In addition to providing patient care and medical education, Dr. Adeyemi is a clinical researcher in the areas of HIV and aging, viral hepatitis, and health disparities, with over 50 publications in peer-reviewed journals.

Clinical Pharmacist Gastroenterology/Hepatology Illinois Department of Corrections Hepatology Telemedicine Clinical Associate Professor Colleges of Pharmacy and Medicine University of Illinois at Chicago University of Illinois Hospital and Health Sciences System Chicago, Illinois Dr. Juliana Chan is a clinical pharmacist and clinical associate professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy and in the Department of Gastroenterology and Hepatology at the UIC College of Medicine. Dr. Chan earned her BS degree in Pharmacy and her PharmD degree from the Massachusetts College of Pharmacy. She then completed a pharmacy practice residency and a specialized residency in gastroenterology and hepatology at the University of Michigan, Ann Arbor. Dr. Chan is a Fellow of the American College of Clinical Pharmacy and a Board Certified Ambulatory Care Pharmacist who teaches and conducts research in gastroenterology and hepatology with a focus on viral hepatitis. She created the first Specialty Hepatitis C Pharmacist-Run Clinic in 2002 at the University of Illinois Medical Center. In 2010, Dr. Chan was part of the implementation committee in establishing the Illinois Department of Corrections Telemedicine Hepatitis Service at the University of Illinois Hospital and Clinics, which she now oversees and through which she treats patients with liver diseases.

Caroline Chapman, JD Senior Director, Litigation and Advocacy Legal Council for Health Justice Chicago, Illinois As the Senior Director of Litigation and Advocacy, Carrie oversees Legal Council for Health Justice’s impact litigation and legislative and administrative advocacy while assisting program directors in supervising legal work. Her practice focuses on improving the Illinois Medicaid program, including advocacy on eligibility, access to treatment, and Early and Periodic Screening, Diagnostic, and Treatment (EPDST). She also uses her experience at building and sustaining medical-legal partnerships to help Legal Council build integrated partnerships with area health care providers for holistic patient care that addresses the social determinants impacting patient health. Currently, she teaches at the DePaul University College of Law, Chicago, as an adjunct faculty member. She received her BA degree from the University of Michigan, Ann Arbor, her MA degree in American Studies from Yale University, New Haven, Connecticut, and her JD degree from the University of Texas, Austin.

Dr. Chan has given numerous national and international invited presentations on viral hepatitis and authored several book chapters and articles published in peer-reviewed professional and scientific journals. She is an active member of many organizations, including the American Association for the Study of Liver Diseases, the American Society of Health-System Pharmacists, and the American College of Clinical Pharmacy.

3

FACULTY

Juliana Chan, PharmD, FCCP, BCACP

FACULTY

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

Gregory Huhn, MD, MPHTM

Stacey B. Trooskin, MD, PhD

Attending Physician, Cook County Health Viral Hepatitis Director, ACCESS Community Health Network Associate Professor Division of Infectious Diseases Rush University Medical Center Chicago, Illinois

Director of Viral Hepatitis Programs Philadelphia FIGHT Clinical Assistant Professor of Medicine Division of Infectious Diseases Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania

Dr. Gregory Huhn is an infectious diseases specialist in Chicago, Illinois. He is currently an attending physician at Cook County Health and the Ruth M. Rothstein CORE Center, and an associate professor of medicine at Rush University Medical Center, where he serves as the Associate Director for the joint Rush University/Stroger Hospital of Cook County Infectious Diseases Fellowship program. He lectures regularly at the University of Illinois, Chicago, School of Public Health, where he is an adjunct assistant professor.

He received his medical degree from Tulane University, New Orleans, Louisiana, where he earned a concomitant Masters of Public Health and Tropical Medicine, trained at Duke University School of Medicine, Durham, North Carolina, in Internal Medicine, and completed his infectious diseases fellowship at Rush University Medical Center in 2005. From 2002 to 2004, Dr. Huhn was based at the Illinois Department of Public Health as the Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC).

Dr. Huhn’s research activities include HIV and viral hepatitis, outbreak investigations, infectious disease surveillance, and risk analysis; he has published over 50 articles in the peer-reviewed literature. The Principal Investigator in a current National Institutes of Health (NIH)-funded, R01 grant examining preexposure prophylaxis adherence for HIV prevention, he has been the Principal Investigator for several pharmaceutical-sponsored clinical trials in HIV and hepatitis C, in addition to developing several investigatorinitiated studies examining novel therapeutic and diagnostic interventions in HIV immunopathogenesis and hepatitis C–associated liver fibrosis. Dr. Huhn also mentors and supervises postgraduate trainees in HIV and viral hepatitis– related longitudinal and retrospective database and survey studies. Since 2015, Dr. Huhn has been the therapeutic advisor for the Simply Speaking HIV Management continuing medical education series, and is a frequent teacher and lecturer across the country.

4

Dr. Stacey Trooskin is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers.

She received her Master of Public Health from Yale University School of Public Health, New Haven, Connecticut, her medical degree from Robert Wood Johnson Medical School, and her Doctor of Philosophy from Rutgers School of Public Health, Piscataway, New Jersey. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania in Philadelphia. Her primary research interest focuses on health care disparities and developing and evaluating models of HCV care. She has been an invited lecturer for numerous presentations focused on HCV, HIV, barriers to care, testing, and linkage to cure. Dr. Trooskin is a member of IDSA and AASLD. She currently sits on the AASLD/IDSA HCV Guidance Panel.

Maggie H. Kaufmann, MA, MPH Visiting Residential Specialist, Public Health Project Director, HepCCATT Case Management Program Community Outreach Intervention Projects (COIP) University of Illinois at Chicago School of Public Health Chicago, Illinois Maggie Kaufmann is the Project Director for the HepCCATT Case Management Program at the University of Illinois at Chicago, School of Public Health, Community Outreach Intervention Projects (COIP). Concurrently, she is the project director for an NIH-funded longitudinal research project investigating the contextual factors influencing HIV/HCV risk among young injection drug users. She has a master’s degree in public health and a master’s in anthropology from the University of Illinois at Chicago. Since joining the CDC-funded project in 2015, Maggie has contributed to the development and implementation of a novel case management program for individuals with chronic hepatitis C designed to address barriers at all levels of the care cascade, to increase access to care. In addition, she has led capacity-building efforts to assist community health centers to integrate hepatitis C care into the primary care setting, including the creation and facilitation of a telehealth training series using the Extension for Community Health Outcomes (ECHO)-Chicago videoconferencing platform.

She has been involved in several federally funded projects focusing on the prevention or management of infectious disease including HIV prevention for migrant populations.

She has also designed and taught undergraduate-level courses in anthropology and on the intersection of race/ ethnicity and health and health care disparities. Her interests include increasing access to care for populations most at risk of new hepatitis C infections including people who inject drugs (PWID), creating novel prevention interventions, and reducing barriers to care.

TARGET AUDIENCE

This activity is intended for a multidisciplinary audience including community-based infectious disease specialists and other HIV treaters, gastroenterology/hepatology clinicians, mental health specialists, substance abuse specialists, correctional health care professionals, public policy/public health officials, hepatitis C virus (HCV) and HIV advocacy groups, payers, and clinical office staff who are engaged in the care of patients with HIV and/or HCV.

EDUCATIONAL OBJECTIVES

Upon completion of this program, the participant should be better able to: • Describe epidemiologic trends in HCV monoinfection and HIV/HCV coinfection within at-risk populations, including men who have sex with men (MSM), people who inject drugs (PWID), and incarcerated individuals • Provide guideline-based treatment for HCV monoinfection and HIV/HCV coinfection • Identify patient, provider, and health care system barriers to effective management of HCV monoinfection and HIV/ HCV coinfection • Implement strategies to overcome risk-cohort–specific challenges to the treatment of HCV monoinfection and HIV/HCV coinfection

PROGRAM DESCRIPTION

Approximately 25% of all individuals infected with HIV are coinfected with HCV.1 Of critical significance, HIV increases the rate of progression of HCV-related hepatic fibrosis, and HCV is associated with a 3-fold increase in HIV antiretroviral therapy–induced liver toxicity.2 Further, these synergistic diseases often occur within adverse socioeconomic conditions that significantly increase the vulnerability and decrease the overall health status of at-risk populations.3 Whereas HIV infection is now effectively manageable, chronic HCV infection is curable. Yet, despite new, highly effective direct-acting antiviral treatment regimens for HCV, their broad-scale use and associated therapeutic successes remain stymied by barriers at the patient, clinician, health care system, and jurisdictional levels.4 The BLOCK HIV/ HCV initiative will provide community-based infectious disease specialists and other HIV treaters with foundational information and practical resources needed to prepare local stakeholders—both clinical and nonclinical—to collaborate in efforts to eliminate HCV within their communities.

5

PREAMBLE

WORKSHOP LEADER/ EXPERT PANELIST

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

PREAMBLE

AGENDA 8:00 am – 8:30 am

Registration and Breakfast

8:30 am – 8:45 am

Overview and Preactivity Polling

8:45 am – 9:15 am

The Epidemiologic Imperative for HCV Elimination Andrew I. Aronsohn, MD

9:15 am – 9:30 am

Barriers to HCV Elimination in HIV/HCV Coinfection Oluwatoyin Adeyemi, MD

9:30 am – 9:45 am

Legal Aspects of HCV Treatment Restrictions Caroline Chapman, JD

9:45 am – 10:30 am

HCV Therapy: State of the Union Nancy S. Reau, MD, FAASLD, AGAF

10:30 am – 10:45 am

BREAK

10:45 am – 11:30 am

Populations in Greatest Need—Men Who Have Sex With Men (MSM) David L. Wyles, MD

11:30 am – 12:15 pm

Populations in Greatest Need—People Who Inject Drugs (PWID) Gregory Huhn, MD, MPHTM

12:15 pm – 1:00 pm

LUNCH

1:00 pm – 1:30 pm

Other Real-World Circumstances—Focus on Corrections Juliana Chan, PharmD, FCCP, BCACP

1:30 pm – 1:45 pm

Community-Based Outreach Success Stories: Philadelphia FIGHT Stacey B. Trooskin, MD, PhD

1:45 pm – 2:00 pm

Introduction to Small-Group Breakouts: Bringing Together Stakeholders and Creating a Collaborative Plan David L. Wyles, MD

2:00 pm – 2:45 pm

Multidisciplinary Small-Group Breakouts: Putting a Plan Into Action Oluwatoyin Adeyemi, MD; Andrew I. Aronsohn, MD; Maggie H. Kaufmann, MA, MPH; Nancy S. Reau, MD, FAASLD, AGAF

2:45 pm – 3:30 pm

Panel Discussion: The Call to Action and Beyond Moderated by David L. Wyles, MD

3:30 pm – 3:45 pm

Closing Statements and Postactivity Polling Moderated by David L. Wyles, MD

REFERENCES

1. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis. https://www.cdc.gov/hepatitis/populations/hiv.htm.

Accessed June 5, 2019.

2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371-386.

6

3. Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco, CA: Jossey-Bass; 2009.

4. National Viral Hepatitis Roundtable (NVHR). Hepatitis C: the State of Medicaid Access. October 23, 2017. https://stateofhepc.org/ wp-content/uploads/2017/10/State-of-HepC _ 2017 _ FINAL.pdf.

Accessed June 5, 2019.

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 6.5 contact hours (0.65 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number—JA4008162-9999-19-748-L02-P) Type of Activity: Application Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Upon registering and completing the activity evaluation, your transcript information will be sent to the National Association of Boards of Pharmacy CPE Monitor service.

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 6.5 contact hours. Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Social Worker Education As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.

Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.

Postgraduate Institute for Medicine maintains responsibility for this course. Social workers completing this course receive 6.5 clinical continuing education credits.

Case Manager Education This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 6.5 clock hours.

INSTRUCTIONS TO RECEIVE CREDIT:

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks. You will receive your certificate from CEcertificate@pimed.com. If you have questions regarding the receipt of your emailed certificate, please contact PIM via email at inquiries@pimed.com.

For Pharmacists: Upon receipt of the completed activity evaluation form, credits will be directly uploaded to CPE Monitor within 30 days.

PREAMBLE

JOINT ACCREDITATION STATEMENT

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity.

All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/ life partners have with commercial interests related to the content of this CME activity: David L. Wyles, MD Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., Merck & Co., Inc.; Grants/Research Support: Gilead Sciences, Inc. Andrew I. Aronsohn, MD Nothing to disclose Nancy S. Reau, MD, FAASLD, AGA Consulting Fees: Abbott, AbbVie Inc., Gilead Sciences, Inc., Merck & Co, Inc.; Grants/Research Support: Genfit, Intercept, Shire Plc Oluwatoyin Adeyemi, MD Consulting Fees: Gilead Sciences, Inc.; Contracted Research (Community grant): Gilead Sciences, Inc. Juliana Chan, PharmD, FCCP, BCACP Consulting Fees: OptumRx

7

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

Caroline Chapman, JD Nothing to disclose

DISCLAIMER

Gregory Huhn, MD, MPHTM Consulting Fees: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., ViiV Healthcare

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Stacey B. Trooskin, MD, PhD Grants/Research Support (Paid to institution): Gilead Sciences, Inc. Maggie H. Kaufmann, MA, MPH Nothing to disclose

PREAMBLE

The PIM planners and managers have nothing to disclose.

The Integritas Communications planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

8

SLIDES

9

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

10

SLIDES

11

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

12

SLIDES

13

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

14

SLIDES

15

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

16

SLIDES

17

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

18

SLIDES

19

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

20

SLIDES

21

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

22

SLIDES

23

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

24

SLIDES

25

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

26

SLIDES

27

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

28

SLIDES

29

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

30

SLIDES

31

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

32

SLIDES

33

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

34

SLIDES

35

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

36

SLIDES

37

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

38

SLIDES

39

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

40

SLIDES

41

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

42

SLIDES

43

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

44

SLIDES

45

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

46

SLIDES

47

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

48

SLIDES

49

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

50

SLIDES

51

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

52

SLIDES

53

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

54

SLIDES

55

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

56

SLIDES

57

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

58

SLIDES

59

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

60

SLIDES

61

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

62

SLIDES

63

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

64

SLIDES

65

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

66

SLIDES

67

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

68

SLIDES

69

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

70

SLIDES

71

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

72

SLIDES

73

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

SLIDES

74

SLIDES

75

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

CLINICAL PRACTICE GUIDELINES »» Considerations for Antiretroviral Use in Patients With Coinfections: Hepatitis C Virus/HIV Coinfection.

US Department of Health and Human Services (DHHS), 2017 (last updated October 2018). https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescentarv/26/hcv-hiv

»» Evaluation and Management of Chronic Hepatitis C Virus (HCV) Infection.

Federal Bureau of Prisons Clinical Guidance. 2018. https://www.bop.gov/resources/pdfs/012018 –hcv–infection.pdf

»» Patients With HIV/HCV Coinfection.

American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), 2017 (last updated May 2018). https://www.hcvguidelines.org/unique-populations/hiv-hcv

CLINICAL RESOURCES »» A Guide to Comprehensive Hepatitis C Counseling and Testing.

Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/hepatitis/resources/professionals/pdfs/ counselingandtestingpc.pdf

»» Harm Reduction Coalition. http://harmreduction.org/

»» HEP Drug Interactions.

University of Liverpool (last reviewed May 2019). https://www.hep-druginteractions.org/

RESOURCE CENTER

ACTION AND ADVOCACY »» Center for Health Law and Policy Innovation (CHLPI) CHLPI advocates for legal, regulatory, and policy reforms to improve the health of underserved populations. It has played a pivotal role in removing Medicaid restrictions on HCV treatment. https://www.chlpi.org/

»» Hepatitis C: State of Medicaid Access CHLPI and National Viral Hepatitis Roundtable (NVHR). https://stateofhepc.org/

»» Hepatitis Education Project (HEP) HEP provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public. http://hepeducation.org/ 76

»» National Hepatitis Corrections Network (NHCN) NHCN, managed by HEP, supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails. http://www.hcvinprison.org/

»» National Viral Hepatitis Roundtable National Viral Hepatitis Roundtable (NVHR) is a coalition working together to eliminate hepatitis B and C in the U.S. It offers practical online resources for practice management.

Coverage/Coding and Billing This page provides information regarding coding and billing for hepatitis services. http://nvhr.org/content/coverage

Implementing EMR Prompts for Baby Boomer Screening This page provides a variety of resources for implementing clinical decision support tools and/or HCV-testing prompts in electronic medical records. http://nvhr.org/EMR

»» Resources for Training Primary Care Providers and Other Health Care Workers About HCV Screening and Linkage to Care This page provides or links to a variety of resources (CARE NAVIGATION TOOLS): • HCV Treatment and Insurance Protocol: Prior Authorization Process • Sample Appeals Letters (Templates) http://nvhr.org/content/provider-resources

»» Project ECHO (Extension for Community Healthcare Outcomes) Project ECHO is a collaborative, telecommunicationsbased model of medical education and care management designed to train primary care clinicians to provide specialty care in rural and underserved communities. https://echo.unm.edu/

»» Substance Abuse and Mental Health Services Administration (SAMHSA): Locator Map SAMHSA provides an interactive national map that facilitates identification of local resources and services for substance use and mental health disorders. https://findtreatment.samhsa.gov/locator

SUGGESTED READING

PATIENT RESOURCES

»» Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.

Allyn PR, et al. Int J STD AIDS. 2018;29(4):334-340.

»» Hepatitis C Information Center The American Liver Foundation’s Hepatitis C Information Center website is a dedicated online information and resource center created in support of individuals impacted

by HCV infection.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670019/pdf/ nihms916054.pdf

»» Hepatitis C virus re-treatment in the era of directacting antivirals: projections in the USA. Chhatwal J, et al. Aliment Pharmacol Ther.

2018;47(7):1023-1031. https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.14527

»» Mechanisms of accelerated liver fibrosis progression during HIV infection.

Debes JD, et al. J Clin Transl Hepatol. 2016;4(4):328-335. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225153/pdf/ JCTH-4-328.pdf

»» High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection.

Girometti N, et al. J Viral Hepat. 2019;26(6):627-634. https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13066

»» Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.

Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491232/

»» Treatment of HCV in persons who inject drugs: treatment as prevention.

Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.

http://hepc.liverfoundation.org/

»» HepatitisC.net HepatitisC.net is a website for people living with HCV that offers education, tools, and resources. Articles are written by people living with or cured of HCV, patient advocates, and medical providers. https://hepatitisc.net/

»» Hepatitis C Questions and Answers for the Public Centers for Disease Control and Prevention (CDC; last reviewed November 2018). The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This patient-directed website addresses basics across the HCV clinical continuum. https://www.cdc.gov/hepatitis/hcv/cfaq.htm

»» Project Inform Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.

Hepatitis C and HIV Coinfection Booklets https://www.projectinform.org/coinfection/

Sexual Transmission of Hepatitis C: A Guide for HIV-Positive Gay Men https://www.projectinform.org/pdf/hcvtoolkit–patient– transmission.pdf

RESOURCE CENTER

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/ cld.626

»» Changing the odds: motives for and barriers to reducing HCV-related sexual risk behavior among HIV-infected MSM previously infected with HCV. Lambers F, et al. BMC Infect Dis. 2018;18(1):678. https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/ s12879-018-3571-1

»» Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Rich ZC, et al. BMC Public Health. 2016;16:994. https://link.springer.com/content/pdf/10.1186%2Fs12889-0163671-z.pdf

77

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

NOTES

78

NOTES

79

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

NOTES

80

85

RESOURCE CENTER

PREAMBLE

FACULTY

RESOURCE CENTER

PREAMBLE

FACULTY

BRINGING LOCAL COMMUNITIES TOGETHER TO ELIMINATE COINFECTION THROUGH KNOWLEDGE AND PARTNERSHIPS

Please visit the CLINICAL

RESOURCE CENTER for additional information and resources

www.ExchangeCME.com/BLOCKHIVHCV19

© 2019 Postgraduate Institute for Medicine and Integritas Communications.

82

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.